Establishment of paclitaxel-resistant cell line and the underlying mechanism on drug resistance

International Journal of Gynecological Cancer

Volumn 22, Issue 9, 2012, Pages 1450-1456

  Zhang, Jingjing ^a,b   Zhao, Jin ^a   Zhang, Wenjing ^a   Liu, Guanyuan ^c   Yin, Dongmei ^b   Li, Jian ^a   Zhang, Sumei ^a   Li, Hongxia ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Gene expression; Ovarian neoplasm; Taxol resistance

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; TETRAZOLIUM; TOPOTECAN;

ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL CYCLE S PHASE; CROSS RESISTANCE; DNA CONTENT; DNA MICROARRAY; DOWN REGULATION; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROARRAY ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; SIGNAL TRANSDUCTION;

EID: 84872324460     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31826e2382     Document Type: Article

References (25)

1. Hoskins WJ, McGuire WP, Brady MF, et al. Combination paclitaxel (taxol)-cisplatin vs cyclophosphamide-cisplatin as primary therapy in patients with suboptimally debulked advanced ovarian cancer. Int J Gynecol Cancer. 1997;7:9-13.
2. McGuire WP, Hoskin WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6.
3. Alberts DS, Hannigan EV, Liu PY, et al. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study. Gynecol Oncol. 2006;100:133-138.
4. Guarneri V, Piacentini F, Barbieri E, et al. Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol. 2010;117:152-158.
5. Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest. 1997;100:1282-1293.
6. Kamazawa S, Kigawa J, Kanamori Y, et al. Multidrug resistance gene-1 is a useful predictor of paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol. 2002;86:171-176.
7. Duan Z, Brakora KA, Seiden MV. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther. 2004;3:833-838.
8. Parekh H, Wiesen K, Simpkins H. Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem Pharmacol. 1997;53:461-470.
9. Minino AM, Heron MP, Murphy SL, et al. Deaths: final data for 2004. Natl Vital Stat Rep. 2007;55:1-119.
10. Krasznai ZT, Friedlander E, Nagy A, et al. Quantitative and functional assay of MDR1/P170-mediated MDR in ascites cells of patients with ovarian cancer. Anticancer Res. 2005;25:1187-1192.
11. Xing H,Wang S, Weng D, et al. Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids. Oncol Rep. 2007;17:117-122.
12. Verlhac MH, de Pennart H, Maro B, et al. MAP kinase becomes stably activated at metaphase and is associated with microtubule-organizing centers during meiotic maturation of mouse oocytes. Dev Biol. 1993;158:330-340.
13. Lee LF, Schuerer-Maly CC, Lofquist AK, et al. Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer. Cancer Res. 1996;56:1303-1308.
14. Blagosklonny MV, Schulte TW, Nguyen P, et al. Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res. 1995;55:4623-4626.
15. Boudny V, Kovarik J. JAK/STAT signaling pathways and cancer. Janus kinases/signal transducers and activators of transcription. Neoplasma. 2002;49:349-355.
16. Omura T, Yoshiyama M, Ishikura F, et al. Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in vivo myocardium of rats. J Mol Cell Cardiol. 2001;33:307-316.
17. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002;8:945-954.
18. Harada D, Takigawa N, Ochi N, et al. A JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an EGFR-activating mutation [published online ahead of print June 19, 2012]. Cancer Sci. doi 2012;02363.x.
19. Lee ES, Ko KK, Joe YA, et al. Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells. Oncol Lett. 2011;21:115-121.
20. Duan Z, Foster R, Bell DA, et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res. 2006;12:5055-5063.
21. Calderwood SK, Khaleque MA, Sawyer DB, et al. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 2006;31:164-172.
22. Ciocca DR, Fuqua SA, Lock-Lim S, et al. Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res. 1992;52:3648-3654.
23. Landriscina M, Amoroso MR, Piscazzi A, et al. Heat shock proteins, cell survival and drug resistance: the mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy. Gynecol Oncol. 2010;117:177-182.
24. Kammanadiminti SJ, Chadee K. Suppression of NF-kappaB activation by Entamoeba histolytica in intestinal epithelial cells is mediated by heat shock protein 27. J Biol Chem. 2006;281:26112-26120.
25. Liu GH, Wang SR, Wang B, et al. Inhibition of nuclear factor-κB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line. Int J Gynecol Cancer. 2006;16:1777-1782.